Maintenance of CD8+ T-cell anergy by CD4+CD25 + regulatory T cells in chronic graft-versus-host disease

Experimental and Molecular Medicine

Volumn 38, Issue 5, 2006, Pages 494-501

  Kim, Juyang ^a   Kim, Hye J ^a   Choi, Woon S ^a   Nam, Seok H ^c   Cho, Hong R ^a,b   Kwon, Byungsuk ^a  

^a University of Ulsan   (South Korea)

^b Ulsan University College of Medicine   (South Korea)

^c Ajou University   (South Korea)

Author keywords

Apoptosis; B lymphocytes; Clonal anergy; Graft vs host disease; T lymphocytes, cytotoxic; T lymphocytes, regulatory

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CLONAL ANERGY; FEMALE; GRAFT VERSUS HOST REACTION; MOUSE; NONHUMAN; PATHOGENESIS;

MURINAE;

EID: 33750704580     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2006.58     Document Type: Article

References (32)

1. + regulatory T cells. Blood 2005;105:4743-8
2. Bimalangshu D, Yang YG, Preffer F, Shimizu A, Swenson K, Dombkowski D, Megan S. The fate of donor T-cell receptor transgenic T cells with known host antigen specificity in a graft-versus-host disease model. Transplantation 1999;68:141-9
3. Blazar BR, Taylor PA, Snover DC, Sehgal SN, Vallera DA. Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin by develop an autoimmune-like syndrome. J Immunol 1999;151:5726-41
4. + T cells during chronic hepatitic C virus infection. J Virol 2005;79:7860-7
5. high regulatory T cells. Blood 2004;103:2410-16
6. + regulatory thymocytes because of their responsiveness to different cytokines. Blood 2004;103:3117-21
7. De Wit D, Van Mechelen M, Zanin C, Doutrelepont JM, Velu T, Gerard C, Abramowicz D, Scheerlinck JP, De Baetselier P, Urbain J, Leo O, Goldman M, Moser M. Preferential activation of Th2 cells in chronic graft-versus-host reaction. J Immunol 1993;150:361-6
8. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003;9:1144-50
9. + T cells to the antitumor immune response. J Exp Med 2005;201:1591-602
10. + regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002;196:389-99
11. + T cells. Blood 2005;105:2206-13
12. + T-cell priming thorough in vivo ligation of glucocorticoid-induced TNF receptor. J Immunol 2006a;176:5223-31
13. Kim J, Choi WS, Kim HJ, Kwon B. Prevention of chronic graft-versus-host disease by stimulation with glucocorticoid-induced TNF receptor. Exp Mol Med 2006b;38:94-9
14. Lee SJ. New approaches for preventing and treating chronic graft-versus-host disease. Blood 2005;105:4200-6
15. Miura Y, Thoburn CJ, Bright EC, Phelps ML, Shin T, Matsui EC, Matsui WH, Arai S, Fuchs EJ, Vogelsang GB, Jones RJ, Hess AD. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood 2004;104;2187-93
16. Morris SC, Cheek RL, Cohen PL, Eisenberg RA. Autoantibodies in chronic graft versus host result from cognate T-B interactions. J Exp Med 1990;171:503-17
17. Murphy WJ. Revisiting graft-versus-host disease models of autoimmunity: new insights in immune regulatory process. J Clin Invest 2000;106:745-7
18. Pals ST, Radaszkiewicz T, Gleichmann E. Allosuppressor- and allohelper-T cells in acute and chronic graft-vs-host disease. J Immunol 1984;132:1669-78
19. Redmond WL, Marincek BC, Sherman LA. Distinct requirements for deletion versus anergy during CD8 T cell peripheral tolerance in vivo. J Immunol 2005;174:2046-53
20. Redmond WL, Sherman LA. Peripheral tolerance of CD8 T lymphocytes. Immunity 2005;22:275-84
21. Rocha B, Grandien A, Freitas AA. Anergy and exhaustion are independent mechanisms of peripheral T cell tolerance. 1995;181:993-1003
22. Rus V, Svetic A, Nguyen P, Gause WC, Via CS. Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. J Immunol 1995;155:2396-406
23. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005;6:345-52
24. Shustov V, Luzina I, Nguyen P, Papadimitriou JC, Handwerger B, Elkon KB, Via CS. Role of perforin in controlling B-cell hyperactivity and humoral autoimmunity. J Clin Invest 2000;106:39-47
25. + immune regulatory cells inhibits graft-versus-host disease after allogeneic disease lethality. Blood 2002;99:3493-9
26. Via CS, Sharrow SO, Shearer GM. Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-versus-host disease. J Immunol 1987;139:1840-9
27. Via CS, Rus V, Gately MK, Finkelman RD. IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graft-versus-host disease. J Immunol 1994;153:4040-7
28. Via CS, Shustov V, Rus V, Lang T, Nguyen P, Finkelman RD. In vivo neutralization of TNF-α promotes humoral autoimmunity by preventing the induction of CTL. J Immunol 2001;167:6281-6
29. + cytolytic T lymphocytes in vivo. Blood 2004;103:177-84
30. + T cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 2005;201:779-91
31. Zhang L, Miller RG, Zhang J. Characterization of apoptosis-resistant antigen-specific T cells in vivo. J Exp Med 1996;183:2065-73
32. + regulatory T cells generated ex vivo with IL-2 and TGF-β suppress a stimulatory graft-versus-host disease with a lupus-like syndrome. J Immunol 2004;172:1531-9